Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04372927 | ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy | terminated | Phase 2 | 1 | University of WashingtonOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | terminated | Phase 2 | 22 | Lung Cancer Group CologneOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03637803 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors |
| terminated |
| Phase 1 / Phase 2 |
| 63 |
| 4D pharma plcINDUSTRY |
| 1 |
| Jun 1, 2023 |
| clinicaltrials |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 31, 2023 | clinicaltrials |
| NCT04849273 | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC | terminated | Phase 1 | 11 | Turning Point Therapeutics, Inc.INDUSTRY | 3 | May 26, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT02382406 | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | terminated | Phase 1 / Phase 2 | 46 | Nisha Mohindra, MDOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03275597 | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | terminated | Phase 1 | 17 | University of Wisconsin, MadisonOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02961283 | Study of ASN003 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 24 | Asana BioSciencesINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT01912625 | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | May 6, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03802058 | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | terminated | Phase 2 | 24 | Wuhan UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05001724 | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent | terminated | Phase 2 / Phase 3 | 16 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04863248 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)(PRESERVE 4) | terminated | Phase 2 | 10 | G1 Therapeutics, Inc.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT03030131 | Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer(IONESCO) | terminated | Phase 2 | 50 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT04698681 | NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial | terminated | — | 20 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03138889 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors(PROPEL) | terminated | Phase 1 / Phase 2 | 162 | Nektar TherapeuticsINDUSTRY | 5 | Mar 10, 2023 | clinicaltrials |
| NCT03838848 | KN046 in Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 120 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT03713944 | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 30 | Nasser HannaOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | terminated | Phase 1 | 13 | Advaxis, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT04438902 | Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment | terminated | Phase 2 | 3 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04622072 | XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 21 | Sihuan Pharmaceutical Holdings Group Ltd.INDUSTRY | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03707925 | Bronchoscopic Laser Ablation of Peripheral Lung Tumors | terminated | N/A | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03656627 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | terminated | Phase 1 | 7 | Alliance Foundation Trials, LLC.OTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03663166 | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 41 | Calithera Biosciences, IncINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT03599518 | DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02513667 | Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma | terminated | Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT02706626 | Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors | terminated | Phase 2 | 32 | Criterium, Inc.INDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04297748 | Bioimaging Study of 89Zr-M7824 in NSCLC | terminated | Phase 1 / Phase 2 | 5 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT02454842 | Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients(TH-4000) | terminated | Phase 2 | 21 | Rain Oncology IncINDUSTRY | 2 | Jan 12, 2023 | clinicaltrials |
| NCT03455556 | Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer | terminated | Phase 1 | 1 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03087448 | Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 9 | University of California, San FranciscoOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | terminated | Phase 1 | 142 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 21, 2022 | clinicaltrials |
| NCT02987998 | Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC | terminated | Phase 1 | 9 | Nathan Pennell, MD, PhDOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT03661567 | Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer | terminated | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03515629 | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | terminated | Phase 3 | 5 | Regeneron PharmaceuticalsINDUSTRY | 3 | Nov 16, 2022 | clinicaltrials |
| NCT05032352 | Predictive Assay for Decision Making in Adjuvant Therapy(PADMA) | terminated | — | 55 | Insight Molecular DiagnosticsINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT03784599 | T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC(TRAEMOS) | terminated | Phase 2 | 28 | The Netherlands Cancer InstituteOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT03430063 | A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | terminated | Phase 2 | 28 | Regeneron PharmaceuticalsINDUSTRY | 9 | Nov 3, 2022 | clinicaltrials |
| NCT04005144 | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | terminated | Phase 1 | 3 | University of California, San FranciscoOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | terminated | Phase 1 | 35 | Aileron Therapeutics, Inc.INDUSTRY | 7 | Oct 10, 2022 | clinicaltrials |
| NCT04398199 | Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients | terminated | Phase 2 | 1 | Wake Forest University Health SciencesOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04861948 | IBI188 Combination Therapy in Solid Tumors | terminated | Phase 1 | 9 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04265534 | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC(KEAPSAKE) | terminated | Phase 2 | 40 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 21, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 13, 2023source: clinicaltrials